Bristol-Myers Squibb's Reliance on Cobenfy Sparks Caution Amid Uncertainty

Morgan Stanley analyst Terence Flynn has maintained a Sell rating on Bristol-Myers Squibb with a $34 price target, citing the company's reliance on Cobenfy, a drug acquired through the Karuna purchase, to counterbalance the loss of exclusivity for older products. Flynn is cautious due to uncertainties surrounding Cobenfy's success in indications such as Alzheimer's Disease Psychosis and the potential risks associated with expanding its label across multiple indications. The outcome of trials such as ADEPT-2, ADEPT-1, and ADEPT-4 will be crucial in determining Cobenfy's broader market potential.

Morgan Stanley analyst Terence Flynn has maintained a Sell rating on Bristol-Myers Squibb (BMY) with a price target of $34.00. Flynn's cautious stance is driven by the company's reliance on Cobenfy, a drug acquired through the purchase of Karuna, to offset the anticipated loss of exclusivity for older products [1].

Cobenfy has shown promise in schizophrenia treatment but faces significant uncertainty in other indications such as Alzheimer's Disease Psychosis (ADP). The first Phase 3 trial results for Cobenfy in ADP are expected in late Q3 or early Q4 of this year [1]. Flynn is particularly concerned about the potential risks associated with expanding Cobenfy's label across multiple indications, including Alzheimer’s agitation, cognition impairment, and bipolar depression I. The success of trials such as ADEPT-2, ADEPT-1, and ADEPT-4 will be crucial in determining Cobenfy's broader market potential [1].

Flynn's cautious rating is also influenced by Bristol-Myers Squibb's need to replace revenue from legacy products. The company faces the challenge of maintaining its revenue stream in the face of these uncertainties, contributing to the Sell rating.

Meanwhile, Morgan Stanley, under the leadership of CEO Ted Pick, is evaluating potential acquisitions to bolster its "core strategy" in wealth and investment management or investment banking. The firm is looking for "tuck ins" that align with its strategy of raising, managing, and allocating capital for clients [2]. Morgan Stanley's focus remains on its existing growth strategy, with a goal of $10 trillion in assets across wealth and investment management, ending the second quarter with $1.7 trillion [2].

References:
[1] https://www.tipranks.com/news/ratings/caution-on-bristol-myers-squibb-reliance-on-cobenfy-amid-uncertain-market-potential-ratings
[2] https://www.advisorhub.com/morgan-stanley-mulling-tuck-in-acquisitions-ceo-says/